Watchlist Momentum: Social media traders have spotlighted Akoya Biosciences ($AKYA) in recent watchlists alongside plays in cybersecurity, drones, and agriculture sectors. Discussions highlight its inclusion amid rising interest in small-cap momentum stocks. The chatter suggests traders view it as a high-potential setup for near-term moves.
Thematic Speculation: Posts frequently group $AKYA with tickers like $IVDA and $UAVS, pointing to technical patterns and short interest as catalysts. Enthusiasm builds around broader market themes driving volatility. Sentiment among participants remains bullish speculative.
Trader Focus: Recurring mentions in portfolio updates underscore growing attention on $AKYA. While specifics on company developments are sparse, the positioning signals optimism for breakout potential. Conversations reflect cautious excitement in a choppy environment.
Note: This discussion summary was generated from an AI condensation of post data.
Akoya Biosciences Revenue
Akoya Biosciences had revenues of $16.6M in Q1 2025. This is a decrease of -9.32% from the same period in the prior year.
You can track AKYA financials on Quiver Quantitative's AKYA stock page.
Akoya Biosciences Government Contracts
We have seen $143,861 of award payments to $AKYA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PHENOIMAGER GOLD SERVICE CONTRACT: $40,320
- PREVENTIVE MAINTENANCE SERVICES FOR ONE (1) AKOYA PHENOIMAGER HT: $39,144
- OPAL REAGENT PACKS: $18,107
- MAINTENANCE AGREEMENT FOR AKOYA MANTRA QUANTITATIVE IMAGING SYSTEM, SERIAL NUMBER MN1548N0024 LOCATED IN BU...: $16,560
- PHENOCYCLER ANTIBODIES: $16,278
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
